Media Pack
News

Current Edition

JCS Volume 15 Issue 2
 
Regional News

Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit

Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been t...
17 March 2022 Regional News Aduhelm | Alzheimer
Continue Reading →
Regional News

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS...
2 February 2022 Regional News Aduhelm | Biogen
Continue Reading →
Regional News

Biogen’s Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame?

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use....
10 November 2021 Regional News Aduhelm | Alzheimer
Continue Reading →
Regional News

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer's disease drug Aduhelm, the company is also feeling the heat from a ...
16 September 2021 Regional News Aduhelm | Alzheimer's
Continue Reading →
 
 
 
jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte